Biotech

All Articles

OS Treatments refiles $6M IPO to finance HER2 medication, preclinical ADCs

.OS Therapies will specify on the NYSE American inventory substitution today by means of a $6.4 thou...

ALX's fizzling CD47 feedback cost sends supply spiraling down

.ALX Oncology's period 2 stomach cancer action rate has actually compromised. After viewing its own ...

Ionis centers eye disease from aim ats of Roche-partnered possibility after records dissatisfy

.One More of Ionis Pharmaceuticals' essential midphase readouts has disappointed expectations, trigg...

Biogen's chief executive officer said no high-risk handle 2023. He's ready to become daring

.While Biogen's pharma peers are actually looking for late-stage assets with little danger, chief ex...

Instil refills pipeline in $2B biobucks handle ImmunOnco

.Instil Biography has actually been a biotech in search of a pipe after it scrapped its lead possess...

Biogen leaves Denali Alzheimer's collab

.Biogen has handed back civil rights to an early Alzheimer's disease program to Denali Therapies, le...

Takeda water faucets brand-new mind of US oncology organization-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, shooting...

Vertex, hammered by AATD again, goes down 2 resources on discard stack

.Vertex's try to manage an unusual hereditary health condition has actually reached one more problem...

Vir gains 3 T-cell engagers coming from Sanofi, gives up 25% of workers

.Vir Medical's second-quarter earnings report wasn't except large updates. The business welcomed a t...

Galapagos stops briefly CAR-T cell therapy litigation over Parkinsonism scenario

.Galapagos has stopped registration in a test of a BCMA-directed CAR-T cell treatment, pushing the b...